Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1959 1
1960 9
1961 5
1962 6
1963 50
1964 52
1965 35
1966 49
1967 46
1968 57
1969 81
1970 81
1971 97
1972 110
1973 103
1974 123
1975 105
1976 80
1977 113
1978 93
1979 112
1980 136
1981 134
1982 166
1983 153
1984 158
1985 195
1986 161
1987 148
1988 168
1989 177
1990 175
1991 180
1992 164
1993 210
1994 233
1995 229
1996 227
1997 190
1998 229
1999 231
2000 275
2001 257
2002 265
2003 289
2004 290
2005 315
2006 280
2007 226
2008 241
2009 212
2010 219
2011 212
2012 200
2013 229
2014 233
2015 222
2016 215
2017 173
2018 172
2019 202
2020 196
2021 202
2022 175
2023 168
2024 164
2025 61

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,202 results

Results by year

Filters applied: . Clear all
Page 1
Depo-Provera.
Sharts-Hopko NC. Sharts-Hopko NC. MCN Am J Matern Child Nurs. 1993 Mar-Apr;18(2):128. doi: 10.1097/00005721-199303000-00015. MCN Am J Matern Child Nurs. 1993. PMID: 8492647
The US Food and Drug Administration finally approved the injectable contraceptive Depo-Provera (DMPA) in October 1992, 25 years after its introduction. Women return to a health facility every 90 days for an intramuscular injection of 150 mg DMPA, which provides them 99% ef …
The US Food and Drug Administration finally approved the injectable contraceptive Depo-Provera (DMPA) in October 1992, 25 years after …
Depo-Provera.
Mesics S. Mesics S. AWHONN Lifelines. 2002 Apr-May;6(2):93. doi: 10.1111/j.1552-6356.2002.tb00034.x. AWHONN Lifelines. 2002. PMID: 11975135 No abstract available.
Depo-Provera and bone density.
Gbolade BA. Gbolade BA. J Fam Plann Reprod Health Care. 2002 Jan;28(1):7-11; quiz 11, 50. doi: 10.1783/147118902101195910. J Fam Plann Reprod Health Care. 2002. PMID: 16259806 Free article. Review. No abstract available.
Depo provera in perspective.
McGoldrick IA. McGoldrick IA. P N G Med J. 1981 Dec;24(4):274-9. P N G Med J. 1981. PMID: 6461984 Review.
In this discussion of Depo-Provera (DMPA) attention is directed to the following: pharmacology and mode of action; clinical considerations; cervical dysplasia; breast cancer; and endometrial carcinoma. DMPA, a microcrystalline suspension of medroxy-progesterone acetate …
In this discussion of Depo-Provera (DMPA) attention is directed to the following: pharmacology and mode of action; clinical considera …
Bone loss in adolescents using Depo-Provera.
Kass-Wolff JH. Kass-Wolff JH. J Soc Pediatr Nurs. 2001 Jan-Mar;6(1):21-31. doi: 10.1111/j.1744-6155.2001.tb00115.x. J Soc Pediatr Nurs. 2001. PMID: 11288500 Review.
ISSUES AND PURPOSE: Contraceptive methods that decrease bone density in a population already deficient in calcium are a rising concern in women's health. CONCLUSIONS: Use of Depo-Provera (DMPA) significantly decreases bone mass density (BMD) in normal adolescents up to the …
ISSUES AND PURPOSE: Contraceptive methods that decrease bone density in a population already deficient in calcium are a rising concern in wo …
Depo-Provera dilemmas.
Cayley J. Cayley J. Br J Fam Plann. 1998 Apr;24(1):1. Br J Fam Plann. 1998. PMID: 9719699 No abstract available.
Depo-provera: contraceptive risk?
Rosenfield A. Rosenfield A. Hastings Cent Rep. 1980 Apr;10(2):4. Hastings Cent Rep. 1980. PMID: 6445344
This writer agrees with Carol Levine that the issue involving depo-provera is both complex and confusing. Comment is offered on some of the conclusions reached by Levine in her article, "Depo-Provera and Contraceptive Risk: A Case Study of Values and Conflicts". ... …
This writer agrees with Carol Levine that the issue involving depo-provera is both complex and confusing. Comment is offered on some …
Depo-Provera: a critical analysis.
Minkin S. Minkin S. Women Health. 1980 Summer;5(2):49-69. doi: 10.1300/j013v05n02_05. Women Health. 1980. PMID: 6451987
This article discusses the research which has led to the controversy of Depo-Provera, and delineates the risks discovered as a result of the studies. Questions are raised as to the advisability of the continued use of this drug. ...In view of the seriousness of the finding …
This article discusses the research which has led to the controversy of Depo-Provera, and delineates the risks discovered as a result …
Use of depo-provera in teens.
Khoiny FE. Khoiny FE. J Pediatr Health Care. 1996 Sep-Oct;10(5):195-201. doi: 10.1016/S0891-5245(96)90001-2. J Pediatr Health Care. 1996. PMID: 8920351 Review.
Currently, depot-medroxyprogesterone acetate is the only contraceptive injection available in the United States. ...In addition, the initial workup, the treatment, and the follow-up of the teen receiving depot-medroxyprogesterone acetate are presented. …
Currently, depot-medroxyprogesterone acetate is the only contraceptive injection available in the United States. ...In additio …
The Depo-Provera debate. Commentary on the article "Depo-Provera, a critical analysis".
Benagiano G, Fraser I. Benagiano G, et al. Contraception. 1981 Nov;24(5):493-528. doi: 10.1016/0010-7824(81)90056-1. Contraception. 1981. PMID: 6459209 Review.
This commentary presents evidence, based on current knowledge, that Depo-Provera is a satisfactory contraceptive with several advantages and some disadvantages, and poses no more unresolved problems than oral contraceptives. ...
This commentary presents evidence, based on current knowledge, that Depo-Provera is a satisfactory contraceptive with several advanta …
10,202 results
You have reached the last available page of results. Please see the User Guide for more information.